Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery
19.12.2025 02:00:00 CET | Business Wire | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area.
MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization.
Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover innovative drug discovery seeds and to accelerate external collaborations.
“We aim to energize our drug discovery research by drawing new ideas from global innovation activities and deepening collaboration with innovation hubs in Japan and overseas. Partnering with MBC BioLabs, which has a proven track record of identifying numerous startups and guiding them toward commercialization, represents a major step forward in these efforts,” said Takeshi Naruse, Managing Executive Officer and Head of R&D at Meiji Seika Pharma.
"MBC BioLabs is excited to partner with Meiji Seika Pharma to empower entrepreneurs and help bring Meiji’s innovations to the U.S. biotechnology ecosystem,” said Flavia Nachbar, Director of Alliances at MBC BioLabs. "This collaboration reflects our shared belief that bold science, backed by the right resources and relationships, can transform human health around the world.”
About MBC BioLabs
MBC BioLabs is a premier life science incubator that provides early-stage biotech companies with the resources and support necessary to thrive. Through its network of state-of-the-art laboratories, industry partnerships, and active bioentrepreneur community, MBC BioLabs enables startups to accelerate research and turn groundbreaking ideas into transformative therapies. Since opening in 2013, MBC BioLabs has helped launch and grow over 500 companies. These companies have brought 176 programs to the clinic, produced 17 approved diagnostics, brought 135 products to the market, and raised over $20 billion. More information is available at www.mbcbiolabs.com
About Meiji Seika Pharma
Meiji Seika Pharma, since it launched penicillin in 1946, has been providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and generic drugs. To further address unmet medical needs, the company is committed to creating next-generation therapies by focusing its R&D on priority areas—infectious diseases, hematologic diseases, and immune-inflammatory diseases—and actively leveraging open innovation. For more information, please visit www.meiji.com/global/pharmaceuticals.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218194500/en/
Contacts
For further information, please contact:
Tomoaki Yoshikawa, PhD
R&D Strategy, Meiji Seika Pharma Co. Ltd.
E-mail: meiji_partnering@meiji.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Defines the Next Era of Commerce: When AI Becomes the Customer2.4.2026 14:00:00 CEST | Press Release
A majority of business leaders are preparing for a world where artificial intelligence doesn’t just assist commerce, it participates in it. New research from Visa (NYSE:V) underscores how quickly that shift is gaining momentum. The Visa Business-to-AI (B2AI) Report, conducted in conjunction with Morning Consult, highlights how AI is already influencing demand. Nearly 40% of Americans have made a purchase they normally would not have considered as a result of using an AI agent or tool. This is an early indication that intelligent systems are beginning to shape how people discover and decide what to buy. The new report also reveals that 53% of U.S. businesses in the survey would allow AI agents to negotiate prices or terms directly with other AI agents on their behalf, signaling that AI-to-AI commerce is poised to scale. At the same time, 71% of businesses say they are willing to optimize products, offers and experiences specifically for AI agents, while 77% are already using or piloting
Traxys Group Completes Acquisition of Carbomax AB Through the Purchase of 100% of Comax22.4.2026 12:01:00 CEST | Press Release
Traxys S.à.r.l., a global trader and merchant in the metals and natural resources sectors, is pleased to announce that the previously announced acquisition of Comax2 AB - the holding company of Carbomax AB - from Investment Aktiebolaget Spiltan and the other shareholders of Comax2 AB has successfully closed. Traxys Group has now acquired 100% of the interests in Comax2 AB, making Carbomax AB a wholly owned subsidiary of Traxys Group. All required Swedish regulatory clearances including foreign direct investment and antitrust approvals have been obtained allowing the parties to finalize the transaction. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. Through this acquisition, Traxys strengthens its presence in the Scandinavian market and reinforces its commitment to advancing sustainable steel production in the region. The combination of Traxys and Carbomax creates significant commercial, operational and
Reply Signs Strategic Collaboration Agreement with AWS to Accelerate AI-Driven Cloud Transformation2.4.2026 10:00:00 CEST | Press Release
Reply [EXM, STAR: REY] announced today that it has signed a strategic collaboration agreement (SCA) with Amazon Web Services (AWS) to accelerate the adoption of cloud and artificial intelligence solutions across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402597802/en/ This strategic collaboration agreement further reinforces Reply’s commitment to enable organizations across industries to harness the full potential of cloud and artificial intelligence technologies. At the core of the SCA is a strong focus on Artificial Intelligence and Generative AI. Leveraging the deep expertise of its specialized companies - Comsysto Reply, Data Reply, Sense Reply, and Storm Reply - Reply supports organizations in designing and deploying enterprise-grade GenAI solutions, including agentic AI systems for autonomous workflows, domain-specialized models for vertical industries, and governance frameworks aligne
Bending Spoons renews tech scholarship for women with €100,000 commitment2.4.2026 09:11:00 CEST | Press Release
Bending Spoons today opened applications for the 2026 edition of its Women in Computer Science Scholarship. The program offers twenty scholarships, each worth €5,000, to university students pursuing technology degrees across Europe and the United Kingdom. This year’s recipients will also be invited to a two-day networking event in Milan in October, fully covered by the company. The initiative is part of a broader set of programs Bending Spoons runs to recognize and support the next generation of technology talent, including merit-based scholarships, networking events, and student competitions. "The students of computer science today will define what the field looks like in the years ahead," said Eva Milenkovska, talent manager at Bending Spoons and lead of the scholarship initiative. "This scholarship is about recognizing the women who are pushing themselves to excel and to help shape the future of the industry." This is the fourth time Bending Spoons has offered this specific scholars
SecurityTech on the Rise: G+D Reports Strong Order Intake and High Resilience in 20252.4.2026 08:30:00 CEST | Press Release
In fiscal year 2025, Giesecke+Devrient (G+D) reaffirmed its position as global leader in SecurityTech for mission-critical infrastructure. In a market where security is becoming essential for technological and societal stability, G+D demonstrates strong growth prospects. In 2025, G+D achieved a record order intake of €3.6 billion (+8%). Revenue increased to €3.2 billion (+1%), although exchange rate effects dampened growth. The key figures underscore the company's strong operational performance and profitability: Adjusted EBIT reached a new high of €211 million. The substantial free cash flow of €119 million provides additional leeway for future investments. With its equally strong segments – Digital Security, Financial Platforms and Currency Technology – G+D boasts a resilient portfolio that effectively cushions market volatility. The company's success reflects this strategic strength, combining technological depth, a global presence and operational reliability. G+D is making targeted
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom